Efficacy and safety of niraparib as maintenance treatment in older patients ( ≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.

CONCLUSIONS: For patients ≥70 years of age receiving niraparib as maintenance treatment in the ENGOT-OV16/NOVA trial, PFS benefits and incidence of any grade or serious treatment-emergent AEs were comparable to results in the younger population. Use of niraparib should be considered in this population.
PMID: 30638768 [PubMed - as supplied by publisher]

Source: Gynecologic Oncology - January 9, 2019 Category: Cancer & Oncology Authors: Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA Tags: Gynecol Oncol Source Type: research